Answers are grounded in this paper and cite their sources.
Objectives: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted.
No takes yet. Share an insight, caveat, or question.
Spellberg et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: